ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,867.60
-0.80%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.275
0.06%
Bitcoin
64,319.75
0.06%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ocugen Inc (OCGN) Quote

Ocugen Inc

Ocugen Inc (OCGN)

NASDAQ
1.18
-0.07
(-5.60%)
Closed April 25 4:00PM
Delayed by 15 minutes
1.19
0.01
(0.85%)
After Hours: 7:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.19
Bid
1.19
Ask
1.20
Volume
7,358,032
1.15 Day's Range 1.2897
0.345 52 Week Range 2.105
Market Cap
300.108M
Previous Close
1.25
Open
1.27
Last Trade
1
@
1.2
Last Trade Time
Financial Volume
$ 8,794,766
VWAP
1.1953
Average Volume (3m)
9,662,002
Shares Outstanding
256,502,434
Dividend Yield
-
PE Ratio
-3.69
Earnings Per Share (EPS)
-0.32
Revenue
-
Net Profit
-81.35M

About Ocugen Inc

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal... Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Ortho,prosth,surg Appl,suply
Website
ocugen.com
Headquarters
Wilmington, Delaware, USA
Founded
2020
Ocugen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OCGN. The last closing price for Ocugen was $1.25. Over the last year, Ocugen shares have traded in a share price range of $ 0.345 to $ 2.105.

Ocugen currently has 256,502,434 shares outstanding. The market capitalization of Ocugen is $300.11 million. Ocugen has a price to earnings ratio (PE ratio) of -3.69.

Ocugen (OCGN) Options Flow Summary

OCGN Options Flow

Overall Flow

Bearish

Net Premium

-73k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

OCGN Latest News

More News

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

April 19 2024
GlobeNewswire Inc.

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

April 12 2024
GlobeNewswire Inc.

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

April 10 2024
GlobeNewswire Inc.

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

April 08 2024
GlobeNewswire Inc.

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen...

April 05 2024
GlobeNewswire Inc.

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3...

April 02 2024
GlobeNewswire Inc.

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE...

April 01 2024
GlobeNewswire Inc.

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

April 01 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.405-25.39184952981.5951.641.1572837261.31274544CS
4-0.54-31.21387283241.732.081.1589938101.60893551CS
120.6356114.6464646460.55442.1050.49596620021.31670046CS
260.799204.3478260870.3912.1050.34558274631.13056885CS
520.3948.750.82.1050.34555306530.85191173CS
156-9.88-89.250225835611.0717.650.345133376856.74118948CS
260-2.05-63.27160493833.2418.770.17178717095.49017436CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.43
(182.34%)
220.51M
AIREreAlpha Tech Corporation
$ 1.14
(88.74%)
35.42M
BOFBranchOut Food Inc
$ 2.0144
(72.17%)
107.44M
LICNLichen China Limited
$ 0.94
(67.86%)
15.08M
AMSTAmesite Inc
$ 3.31
(65.50%)
70.3M
NCINeo Concept International Group Holdings Ltd
$ 2.33
(-75.47%)
8.33M
GCTKGlucoTrack Inc
$ 0.466
(-38.68%)
1.7M
ISUNiSun Inc
$ 0.0922
(-38.12%)
9.79M
VAXXVaxxinity Inc
$ 0.1326
(-33.70%)
4.95M
EVOEvotec SE
$ 5.2199
(-31.77%)
1.55M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.43
(182.34%)
220.51M
TSLATesla Inc
$ 162.13
(12.06%)
181.24M
SQQQProShares UltraPro Short QQQ
$ 11.81
(-0.84%)
148.21M
BOFBranchOut Food Inc
$ 2.0144
(72.17%)
107.44M
NKLANikola Corporation
$ 0.6206
(-2.31%)
80.82M

OCGN Discussion

View Posts
vieuxcarre vieuxcarre 4 days ago
Nope
👍️0
harry crumb harry crumb 4 days ago
Stop, really….
👍️0
harry crumb harry crumb 4 days ago
We’ll see 1$ again thats for sure imo
👍️0
harry crumb harry crumb 6 days ago
Stop, short it u’l make money $$$$$
👍️0
vieuxcarre vieuxcarre 6 days ago
Only thing bleeding is your mums puss lmoa
👍️0
vieuxcarre vieuxcarre 6 days ago
Learn to spell
👍️0
harry crumb harry crumb 6 days ago
Easy Money made again today, bleeding to under 1$ again folks, lets keep er going
👍️0
harry crumb harry crumb 6 days ago
Yur not right!
👍️0
investingnotgambling investingnotgambling 6 days ago
RSI at its lowest since early February when the 50 MA crossed the 200. Room to run here if buyers show up and the shorts start covering.
👍️0
vieuxcarre vieuxcarre 7 days ago
Tool
👍️0
harry crumb harry crumb 7 days ago
Running out soon! Dilution, dilution dilution coming, no partner, no warrants, cash supply is dwindling fast
👍️0
sgunderbarth sgunderbarth 7 days ago
Gm ocuhub. Company has cash. I like it.
👍️0
harry crumb harry crumb 1 week ago
Your the guy that started responding to the truth about this loser, which it is an always will be. No partner, no warrants, no revenue, no whale investors, no buyout, an most of all, they are running out of cash! Nothing more than 1 of the 97.5%of bio company’s that fail. Short it an make money an keep your mouth closed, GL
👍️0
vieuxcarre vieuxcarre 1 week ago
Child’s play
👍️0
vieuxcarre vieuxcarre 1 week ago
Like going down on your mom’s muff.
👍️0
harry crumb harry crumb 1 week ago
Oh we are $$$$, another 30k profit day
👍️0
harry crumb harry crumb 1 week ago
Down this turd goes, lets push it to 1.00, .50, .10, lets roll! $$$$$$
👍️0
vieuxcarre vieuxcarre 1 week ago
Better yet. Go hop back on your nipple
👍️0
harry crumb harry crumb 1 week ago
We have a huge office, sorry chump, go back to your moms lapp and suck your thumb
👍️0
vieuxcarre vieuxcarre 1 week ago
Douche
👍️0
vieuxcarre vieuxcarre 1 week ago
You’re the one living in your parents basement
👍️0
harry crumb harry crumb 1 week ago
No partner, no revenue, no drug on the market, sorry folks, they’l be out of money real soon, dilution coming, we’l cover at .50! It’s coming
👍️0
harry crumb harry crumb 1 week ago
Shut up you scumbag, or we’l tell your mom, go back in yur closet and count yur pennies! Lmao
👍️0
vieuxcarre vieuxcarre 1 week ago
You’re a fuckin loser and clueless moron
👍️0
harry crumb harry crumb 1 week ago
Like we said, u hav no clue who we are an no clue whats about to happen sooner than you think, read up on the ceo and the zero success rate he has. Be careful this is not a bio winner imo
👍️0
Tradrdug17 Tradrdug17 2 weeks ago
If I were you, I would start looking for another stock board to terrorize cuz as soon as they get fda approval, your shorting days are over. You know it’s coming. We can all put up with your nonsense for a little while longer because when products hit the market, this stock will explode. Then it will be bye bye crumbs
👍️0
harry crumb harry crumb 2 weeks ago
Lol, if you only knew…. $$$$$$
👍️0
vieuxcarre vieuxcarre 2 weeks ago
Keep on shorting. You’ll soon be crumbled topping on my cake
👍️0
vieuxcarre vieuxcarre 2 weeks ago
Keep shorting.
👍️0
harry crumb harry crumb 2 weeks ago
Its all a scam imo
👍️0
harry crumb harry crumb 2 weeks ago
Great, shorting this turd is a dream $$$$$
👍️0
vieuxcarre vieuxcarre 2 weeks ago
How’s crumb cake doing
👍️0
investingnotgambling investingnotgambling 2 weeks ago
FDA approval and this might go red in after hours. Yup, makes total sense. Gotta love the stock market.
👍️0
sgunderbarth sgunderbarth 2 weeks ago
Good evening, ocuhub

OCGN
👍️0
glenn1919 glenn1919 3 weeks ago
OCGN...................................https://stockcharts.com/h-sc/ui?s=OCGN&p=W&b=5&g=0&id=p86431144783
👍️0
vieuxcarre vieuxcarre 3 weeks ago
Yeah you keep trying. Good for you.
👍️0
harry crumb harry crumb 3 weeks ago
Wont be for long lol
👍️0
vieuxcarre vieuxcarre 3 weeks ago
Good call crumble.
👍️0
vieuxcarre vieuxcarre 3 weeks ago
Clueless
👍️0
glenn1919 glenn1919 3 weeks ago
OCGN........................................https://stockcharts.com/h-sc/ui?s=OCGN&p=W&b=5&g=0&id=p86431144783
👍️0
harry crumb harry crumb 3 weeks ago
Yes the price is going down, everyone can see that. Maybe they come up with some miracle investor who donates for a tax write off, but i doubt it. Dilution and rs are in store imo, short play here is bank imo, gl to ya, b careful
👍️0
vieuxcarre vieuxcarre 3 weeks ago
Will not. And you are going down
👍️0
harry crumb harry crumb 3 weeks ago
Stop, you know the deal, going nowhere
👍️0
vieuxcarre vieuxcarre 3 weeks ago
You’re a fool
👍️0
harry crumb harry crumb 3 weeks ago
So with all this so called excitement, theres no partner, there’s no funding, there’s no individual investors, there is no new news other than they will be out of cash by the end of the year or sooner, hhhmmmm, looks like inhaled company dilution about to happen any day now, sad and scary for anything positive here imo
👍️0
harry crumb harry crumb 3 weeks ago
$$$$$ again today
👍️0
harry crumb harry crumb 3 weeks ago
B under 1$ soon enough lol, no news on a partner, no news at all on anything, the perfect short folks $$$$$
👍️0
vieuxcarre vieuxcarre 4 weeks ago
STFU CLUELESS
👍️0
harry crumb harry crumb 4 weeks ago
If they announce an offering then there’s no partner, just saying. They are running out of money, about a year left.
👍️0
vieuxcarre vieuxcarre 4 weeks ago
Bahhahahaha
👍️0

Your Recent History

NASDAQ
OCGN
Ocugen
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved